national disclosure summit on Pharmaceutical and Medical Device Disclosure, Transparency and Aggregate Spend Conference



Overview | Agenda/Faculty Materials | Promotional Opportunities
Speaking Proposals | Administration | Log In | Past Events | Contact Us | Home



THE THIRD NATIONAL DISCLOSURE SUMMIT CONTENT IS NOW AVAILABLE
IN VARIOUS POST CONFERENCE FORMATS

The Third National Disclosure Summit conference content is now available in a variety of formats.

You may purchase the Summit streaming content in the following formats: Flash Drive or online archive (6 months). You may also purchase individual presentations in an online archive (6 months) format.

YOU CAN PURCHASE JUST THE THIRD NATIONAL DISCLOSURE SUMMIT CONTENT AS FOLLOWS:

Online Archive of 2011 Third National Disclosure Summit Presentations today!
Complete conference: $595
Order Now

Flash Drive of 2011 Third National Disclosure Summit Presentations today!
$595
Order Now

FINALLY YOU MAY PURCHASE THE THIRD NATIONAL DISCLOSURE SUMMIT INDIVIDUAL PRESENTATIONS:
Click here to purchase individual presentations for $59.95 in online archive format (6 months of access - 24/7).





national pharmaceutical and medical device disclosure and transparency conference

THIRD ANNUAL SUMMIT ON DISCLOSURE, TRANSPARENCY AND AGGREGATE SPEND FOR DRUG, DEVICE AND BIOTECH COMPANIES

March 9 - 11, 2011

Onsite:
Wardman Park Hotel, Washington, DC

Online:
Live and Archived for 6 Months

MEDIA PARTNERS










SUMMIT GRANTORS

GOLD GRANTOR

SILVER GRANTOR

BRONZE GRANTORS



























DISCLOSURE SUMMIT IS A




THIRD ANNUAL SUMMIT ON DISCLOSURE, TRANSPARENCY AND
AGGREGATE SPEND FOR DRUG, DEVICE AND BIOTECH COMPANIES

A Pharma Congress Conference
March 9 - 11, 2011

ONSITE
Wardman Park Hotel
Washington, DC


OR
ONLINE
In your own office or home live via the Internet
with 24/7 access for six months


KEYNOTE SPEAKERS


Eric G. Campbell, PhD
Associate Professor of Medicine, Harvard Medical School, Director of Research, Mongan Institute for Health Policy, Boston, MA

Michael K. Loucks, Esq.
Partner, Skadden Arps LLP, Former First Assistant US Attorney, US Attorney's Office for the District of Massachusetts, Washington, DC

Jack Mitchell
Chief of Oversight and Investigations, Special Committee on Aging, United States Senate, Former Director, Commissioner's Office of Special Investigations, US Food and Drug Administration, Washington, DC

Mary E. Riordan, Esq.
Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services, Washington, DC

James G. Sheehan, Esq.
New York State Medicaid, Inspector General, Former Associate United States Attorney, US Attorney's Office, Eastern District of Pennsylvania, Albany, NY

CO CHAIRS



Frank Bigley
Chief Compliance Officer, Novo Nordisk Inc., Princeton, NJ

William E. Buzzeo, MS
Vice President and General Manager Compliance Solutions Division, Cegedim Relationship Management, Richmond, VA

Sarah K. Giesting, Esq.
Associate, Epstein Becker & Green, New York, NY

Jonathon Kellerman
Principal, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP, Florham Park, NJ

Karen Lowney
Senior Director, Global Compliance, Cephalon, Frazer, PA

Rore Middleton, Esq.
Senior Manager, Corporate Compliance, Purdue Pharma LP, Stamford, CT

Paul J. Silver
Managing Director and Practice Leader, Life Sciences Advisory Services Practice, Huron Consulting Group, LLC, Atlanta, GA

Heidi Straub
Senior Director, Physician Aggregate Spend Team (PhAST), Eli Lilly and Company, Indianapolis, IN

Jack T. Tanselle
Director, Navigant Consulting, Inc., Chicago, IL

FEATURING SESSIONS ON

  • The Basics of Disclosure/Aggregate Spend Technology Solutions
  • 2010 US and Global Transparency Management Industry Survey Findings
  • Training the New Disclosure/Aggregate Spend Compliance Workforce
  • Disseminated Data Utilization in Anti-Kickback and False Claims Enforcement
  • Best Practices in Structure: Project Management and Staffing
  • Best Practices in Training and Branding
  • Best Practices in Program Ownership: Compliance, Finance, HR and/or IT
  • Best Practices in Communicating Transparency Initiatives to Customers
  • Best Practices in Capturing Correct Information and Ensuring Accuracy
  • Best Practices: A Comprehensive Approach to Managing your HCP Spend

  • Managing Change in Transparency Programs: Process, Change Management and Strategic Decisions
  • Why Most Drug and Device Companies will Comply Prior to the Sunshine Act Deadline
  • After Sunshine: Preparing to Deal with the Likely Consequences of Public Disclosures
  • The Role of the Office of Inspector General
  • The Continuing Role of Congress in Sunshine Act Implementation
  • State Disclosure Laws Update
  • How Disclosure is Reshaping State Enforcement Initiatives
  • Aggregate Spend 2.0: MD Disclosure
  • Drug Sample Disclosure: the Next Horizon
  • Complying with Vermont's Drug Sample Requirement
  • Company Approaches to Aggregate Spend Technology Solutions
  • Aggregate Spend Technology Solution Provider Roundtable
  • FEATURED FACULTY





    Ben Carmel
    Aggregate Spend Technology Specialist, Polaris Management Partners, New York, NY

    Mitch Chi
    Senior Vice President Sales, Health Market Science, King of Prussia, PA

    Jennifer Colapietro
    Partner, Transparency and Aggregate Spend Practice Lead, PricewaterhouseCoopers LLP, Florham Park, NJ

    Danielle M. Drissel, Esq.
    Associate, Hogan Lovells, US, LLP, Washington, DC

    Dan S. Dunham
    Vice President, Corporate Compliance, and Chief Compliance Officer, Astellas Pharma US, Inc., Deerfield, IL




    Marc Eigner, MS
    Partner, Polaris Management Partners, New York, NY




    Jennifer Gomez
    Associate Director, CRM IT, Shire, Wayne, PA




    Lori Greene, MA
    Senior Principal, R-Squared, Director, Commercial Compliance, Stiefel Laboratories, Inc., Atlanta, GA



    Bill Hadad
    Consultant - State Reporting Operations, Lilly USA, LLC - Bio-Medicines, Indianapolis, IN

    Seth H. Lundy, Esq.
    Partner and Deputy Chair, FDA and Life Sciences Practice Group, King & Spalding LLP, Washington, DC



    Kim Mills
    Senior Vice President, AHM Compliance Solutions, Bridgewater, NJ

    Patrick M. Mooty, Esq.
    Senior Director, Ethics and Compliance, Fresenius Medical Care, Waltham, MA


    Wendy Morgan, Esq.
    Chief of Public Protection Division, Vermont Office of the Attorney General, Montpelier, VT

    Kirk Ogrosky, Esq.
    Partner, Arnold & Porter, Former Deputy Chief, Fraud Section, Criminal Division, US Department of Justice; Former Assistant US Attorney, US Attorney's Office for the Southern District of Florida; Former Assistant Attorney General, Kentucky, Washington, DC

    John Patrick Oroho, Esq.
    Executive Vice President, Porzio Pharmaceutical Services, Principal, Porzio, Bromberg & Newman PC, Morristown, NJ

    Kathleen A. Peterson, Esq.
    Partner, Health Care and Life Sciences Practice Group, Epstein Becker & Green, Washington, DC

    John Poulin
    Chief Solutions Architect, Life Sciences Advisory Services Practice, Huron Consulting Group, LLC, New York, NY




    Marjorie E. Powell, Esq.
    Senior Assistant General Counsel, Pharmaceutical Research and Manufacturers of America, Washington, DC



    Christina F. Rich, Esq.
    Vice President, Business Ethics and Compliance, Cardiac and Vascular Group, Medtronic, Minneapolis, MN




    Luanna Saulino
    Associate Director, State Law Reporting, Bayer Healthcare, Wayne, NJ

    Trudy J. Seeley, Esq.
    Compliance Manager, State Law Compliance and US Corporate Compliance, sanofi-aventis, Bridgewater, NJ

    Don Soong
    Senior Director, Compliance Solutions Development, Cegedim Dendrite, Bedminster, NJ

    James C. Stansel, Esq.
    Partner and Co-head, Global Life Sciences Team, Sidley Austin LLP, Former Acting General Counsel, US Department of Health and Human Services, Washington, DC

    Jon Wilkenfeld, MBA
    President, Potomac River Partners, Vienna, VA

    Ronald L. Wisor, Jr., Esq.
    Partner, Hogan Lovells, US, LLP, Washington, DC

    Kim Zahan
    Director R&D Financial Compliance, GlaxoSmithKline, King of Prussia, PA
    ATTENDANCE OPTIONS
    TRADITIONAL CONFERENCE ATTENDANCE
    By attending onsite, you will be able to more completely immerse in the subject matter, get professional networking opportunities, and interact with the faculty. Register for Preconference and/or Conference.

    LIVE AND ARCHIVED INTERNET ATTENDANCE
    Watch the conference plenary session in live streaming video and listen to streaming audio of track sessions over the Internet and at your convenience at any time 24/7 for the six months following the event.

    The archived conference includes speaker videos and coordinated PowerPoint presentations.

    Pros: Live digital feed and 24/7 Internet access for next six months; Accessible in office, at home or anywhere worldwide with Internet access; Avoid travel expense and hassle; No time away from the office

    INTERNET INTERFACE SAMPLE

    Click here for a sample stream




    We subscribe to the HONcode principles of the HON Foundation. Click to verify.



    Overview | Agenda/Faculty Materials | Promotional Opportunities
    Speaking Proposals | Administration | Log In | Past Events | Contact Us | Home




    © Health Care Conference Administrators
    Contact Webmaster